Spots Global Cancer Trial Database for Aranesp and Neulasta in Patients With Sarcoma Receiving Adriamycin and Ifosfamide

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Aranesp and Neulasta in Patients With Sarcoma Receiving Adriamycin and Ifosfamide

Official Title: A Pilot Study of Aranesp (Darbepoetin Alfa) and Pegfilgrastim (Neulasta) in Patients With Sarcoma Receiving Adriamycin and Ifosfamide

Study ID: NCT00283621

Conditions

Sarcoma

Interventions

Aranesp (darbepoetin alfa)

Neulasta (pegfilgrastim)

Adriamycin

Ifosfamide

Study Description

Brief Summary: To determine the percentage of patients and number of cycles in which a packed red blood cell transfusion was administered due to anemia and in which antibiotics were administered due to neutropenic fever.

Detailed Description: The use of hematopoietic growth factors have been shown to reduce neutropenic complications and red cell transfusion requirements associated with chemotherapy. This trial will study the combination of pegfilgrastim and darbepoetin alfa administered once per cycle of chemotherapy. Prior experience with growth factors in this setting provides historical data for comparison of safety and activity of these newer longer acting growth factors in reducing the incidence of febrile neutropenia requiring antibiotics and anemia requiring transfusions. The once dosing per cycle would simplify the patient management and would improve patient convenience and compliance.